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HHT shows clinical variability within and between families. Organ site and prevalence
of arteriovenous malformations (AVMs) depend on the HHT causative gene and on
environmental and genetic modifiers. We tested whether variation in the functional ENG
allele, inherited from the unaffected parent, alters risk for pulmonary AVM in HHT1
mutation carriers who are ENG haploinsufficient. Genetic association was found between
rs10987746 of the wild type ENG allele and presence of pulmonary AVM [relative risk = 1.3
(1.0018–1.7424)]. The rs10987746-C at-risk allele associated with lower expression of
ENG RNA in a panel of human lymphoblastoid cell lines (P = 0.004). Moreover, in
angiogenically active human lung adenocarcinoma tissue, but not in uninvolved quiescent
lung, rs10987746-C was correlated with expression of PTPN14 (P = 0.004), another
modifier of HHT. Quantitative TAQMAN expression analysis in a panel of normal lung
tissues from 69 genetically heterogeneous inter-specific backcross mice, demonstrated
strong correlation between expression levels of Eng, Acvrl1, and Ptpn14 (r2
12
= 0.75–0.9,
P < 1 × 10− ), further suggesting a direct or indirect interaction between these three
genes in lung in vivo. Our data indicate that genetic variation within the single functional
ENG gene influences quantitative and/or qualitative differences in ENG expression that
contribute to risk of pulmonary AVM in HHT1, and provide correlative support for PTPN14
involvement in endoglin/ALK1 lung biology in vivo. PTPN14 has been shown to be
a negative regulator of Yap/Taz signaling, which is implicated in mechanotransduction,
providing a possible molecular link between endoglin/ALK1 signaling and mechanical
stress. EMILIN2, which showed suggestive genetic association with pulmonary AVM,
is also reported to interact with Taz in angiogenesis. Elucidation of the molecular
mechanisms regulating these interactions in endothelial cells may ultimately provide more
rational choices for HHT therapy.
Keywords: endoglin, ACVRL1, PTPN14, EMILIN2, lung, arteriovenous malformations
INTRODUCTION
Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal
dominant disorder resulting from loss of function mutations pre-
dominantly in ENG (HHT type 1) or ACVRL1 aka ALK1 (HHT
type 2) (Shovlin, 2010; Faughnan et al., 2011). These genes encode
cell surface receptors which are components of the TGF-β/BMP
signal transduction pathways active predominantly in endothelial
cells. Endoglin (ENG) is a trans-membrane glycoprotein similar
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to the TGF-β type III receptor and ALK1 (ACVRL1) is a trans-
membrane serine threonine kinase TGF-β/BMP type I receptor
(Lebrin et al., 2004; Lopez-Novoa and Bernabeu, 2010; Pardali
et al., 2010; Cunha and Pietras, 2011). Affected HHT patients typ-
ically present during adolescence with muco-cutaneous telang-
iectases and frequent severe episodes of epistaxis (Shovlin, 2010;
Faughnan et al., 2011). Telangiectases result from abnormal vas-
cular remodeling, leading to capillary breakdown and consequent
shunting of arterioles directly into venules with no intervening
capillary bed (Guttmacher et al., 1995). Blood vessel walls of
lesions are dilated and weak, leading to frequent hemorrhage.
Epistaxis and bleeding from gastrointestinal tract telangiectases
can result in severe anemia and the need for frequent blood
transfusions. HHT is highly penetrant, but with age dependent
expression of different clinical features (Shovlin, 2010; Faughnan
et al., 2011).
In addition to telangiectases, approximately half of HHT
patients develop more serious complications, namely visceral
AVMs that can occur anywhere but are mostly found in lung,
brain, and liver. AVMs also involve shunting of blood directly
from artery to vein. Large AVMs lead to local hypoxia and are
prone to hemorrhage. Brain AVMs are often asymptomatic, but
can cause seizures or hemorrhage. Pulmonary AVMs are at high
risk of thromboembolism, resulting in thrombotic stroke or cere-
bral abscess. One of the features of HHT is a large range in
clinical severity and prevalence of AVMs (Letteboer et al., 2006;
Lesca et al., 2007; Sabba et al., 2007). Some phenotypic variability
can be accounted for by genetic heterogeneity, for example lung
AVMs are more common in HHT1, whereas hepatic AVMs are
more prevalent in HHT2 (Letteboer et al., 2006; Lesca et al., 2007;
Sabba et al., 2007). Nevertheless, the large intra-familial range in
clinical severity suggests that local environmental stresses, such
as wounding and/or inflammation (van Laake et al., 2006; Park
et al., 2009; Garrido-Martin et al., 2014) and/or germline genetic
modifiers (Benzinou et al., 2012; Kawasaki et al., 2014), may
contribute to precipitation of telangiectases or AVMs. Localized
somatic mutation (Akers et al., 2009; McDonald et al., 2014)
might also contribute to the risk of clinical progression, although
this has not been definitively tested. Identification of disease-
modifying germline genetic variants may provide a deeper molec-
ular understanding of the process of AVM formation that might
be harnessed for therapeutic design purposes.
In order to uncover possible molecular mechanisms that con-
tribute to pulmonary AVMs, we previously undertook a screen
for genetic loci that associate with pulmonary AVM prevalence
within the HHT population (Benzinou et al., 2012). As TGF-β1
is known to bind both endoglin and ALK1 and attenuate or acti-
vate signaling downstream of ALK1, we hypothesized that genetic
modifiers of TGF-β1 (Tgfbm’s) may influence the vascular out-
come of HHT. We therefore screened genes within human loci
syntenic to mouse Tgfbm2 and Tgfbm3, both suppressors of a
lethal prenatal vascular dysplasia observed in some Tgfb1-/-mice
(Benzinou et al., 2012; Kawasaki et al., 2014).We also screened for
genetic association within 72 additional human genes, genome-
wide, that encode components of the TGF-β or BMP signaling
pathways, or that had been implicated in regulating or being reg-
ulated by TGF-β or BMP (Benzinou et al., 2012). While we found
only one gene, PTPN14, encoding protein tyrosine phosphatase,
non-receptor type 14 (PTPN14), that fit our stringent genetic cri-
teria for being a modifier of pulmonary AVM incidence in HHT
(Benzinou et al., 2012), the current study focuses on weaker but
still instructive genetic associations. We also provide further cor-
relative evidence that PTPN14 interacts with ENG in the lung
in vivo.
METHODS
HHT HUMAN SUBJECTS
Study protocols were approved by local ethics committees at
all institutions, and informed consent was obtained from each
subject before participation in the studies. Initially, 649 Dutch
Caucasians and 72 Dutch Antillean Blacks were genotyped. These
were selected from a panel consisting of probands and family
members from a total of 137 different families screened for HHT.
All manifestations of HHT were recorded for both probands and
family members. The clinical diagnosis of HHT was established
according to the Curaçao criteria (Faughnan et al., 2011), which
are clinical features of epistaxis, multiple telangiectases, visceral
AVMs and a first-degree relative with HHT. A diagnosis of HHT
is considered definitive if three criteria are present, possible if
two criteria are present and unlikely if fewer than two criteria
are present. Mutation carrier status was confirmed by molecular
analysis. Most probands and family members were screened for
visceral manifestations at St Antonius Hospital, which specializes
in the diagnosis and treatment of HHT. Screening for the presence
of pulmonary AVMs was performed routinely by chest radiog-
raphy and by measuring partial oxygen tension in arterial blood
and, if abnormal, followed by the 100% oxygen right-to-left shunt
test. Based on this analysis, patients with suspected pulmonary
AVMs were offered conventional angiography, digital subtraction
angiography of the pulmonary arteries or computed tomography
(CT) of the chest. In some patients, pulmonary AVMs were diag-
nosed using high-resolution CT and/or contrast trans-thoracic
echocardiography.
HHT clinical diagnosis in the French cohort was also estab-
lished according to the Curaçao criteria. Mutation carrier status
was confirmed by molecular diagnosis (heteroduplex analysis
or denaturing high performance liquid chromatography and
sequencing). The 222 French patients included in the present
study all carried a mutation in either ENG (n = 76) or ACVRL1
(n = 146), and 43% of them had pulmonary AVMs (74% for
HHT1 patients and 27% for HHT2 patients). Familial struc-
tures included 111 singletons, 40 duos, 2 trios, 5 quartets, and 1
family with 5 individuals. The diagnosis of pulmonary involve-
ment was made either in patients presenting symptoms (for
example, dyspnoea and cyanosis) or complications (mainly brain
abscess), or in asymptomatic HHT patients who underwent
screening using contrast trans-thoracic echocardiography, chest
radiograph and/or oxygen shunt test as described. Screening
for pulmonary AVMs was also recommended to asymptomatic
patients and accepted by a majority of them (Lesca et al.,
2007). The “no-pulmonary AVM” cohort should thus be con-
sidered as either negative for pulmonary AVMs or having only
small clinically-insignificant pulmonary AVMs at the time of
assessment.
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LYMPHOBLASTOID CELL LINES
Affymetrix gene expression data for 61 human lymphoblastoid
cell lines derived from blood samples from Utah residents of
Northern and Western European Ancestry from the CEPH col-
lection (CEU) (Cheung et al., 2005), were downloaded from
Gene Expression Omnibus (GEO), and matching genotype data
for rs10987746 was downloaded from the International HapMap
Project website. Expression levels of ENG and PTPN14 were
compared by rs10987746 genotype. Since the rs10987746-C/C
genotype was unusually underrepresented in this panel (n = 7),
and showed no statistically significant difference in expression
from the rs10987746-T/C genotype, these two genotypes were
pooled and their combined expression levels compared to that of
the rs10987746-T/T genotype. P-values (ANOVA) were calculated
using Tukey’s HSD in R Development Core Team (2011).
HUMAN LUNG CANCER SUBJECTS
All samples were obtained from patients with informed consent
under the IRB approval (ID: 10-03352) granted by the Committee
on Human Research at the University of California, San Francisco
(UCSF). Paired RNA and DNA samples from human primary
lung adenocarcinomas and uninvolved “normal” lung tissue were
obtained from patients undergoing tumor debulking surgery at
UCSF. Each tumor sample consisted of at least 50% tumor cells.
MICROARRAY EXPRESSION ANALYSIS OF PAIRED NORMAL AND
ADENOCARCINOMA LUNG TISSUE FROM LUNG CANCER PATIENTS
RNA was extracted with Trizol followed by DNAse I treatment
and purification (RNeasy RNA purification kit, Qiagen). The
purified RNA was quantified with Nanodrop and QC checked
by Agilent Bioanalyzer. Gene expression was measured with the
Illumina Human Whole Genome 6 2.0 array (Illumina Inc., San
Diego, CA, USA). Sample preparations, hybridization and scan-
ning were performed according to manufacturer’s instructions.
Briefly, 200 ng of total RNA was prepared to make cRNA by
using Illumina TotalPrep RNAAmplification Kit (Ambion). First-
strand complementary DNA was generated with T7 oligo (dT)
primer and ArrayScript and then second cDNA was also made
with DNA polymerase. Biotin-NTP with T7 enzyme mixes was
used to make biotinylated cRNAs. The labeled cRNAs were puri-
fied, quantified and checked again using the Bioanalyzer. The
labeled cRNA target was used for hybridization and scanning
according to Illumina Human Whole Genome 6 2.0 array pro-
tocol. Probes with present/absent call ≥0.05 assessed by Illumina
Beadstudio software, were marked absent. Raw microarray data
were quantile normalized and log2-transformed. Statistical anal-
ysis was performed with R version 2.13 (R Development Core
Team, 2011).
HUMAN SNP SELECTION
Gene-centric tag-SNPs were chosen on the basis of being non-
synonymous coding polymorphisms, potential splice site variants
or inferred to disrupt important gene regulatory sites (that is,
microRNAs and transcription factor binding sites, and so on)
using the UCSC genome server. We further looked for SNPs
located in highly conserved regions in the 3′ UTR. This first set
of SNPs was complemented by tag-SNPs using a tag approach
with the HapMap phase II database (http://www.hapmap.org)
by “force including” the first set of variants using the Haploview
Tagger and by searching for additional tag-SNPs. Selected SNPs
were estimated to give ∼85% coverage of any chosen gene.
HUMAN GENOTYPING AND QUALITY CONTROL
We previously screened genetic variants for association with the
presence of pulmonary AVM in HHT patients from 137 Dutch
HHT families. The first screen included 649 Dutch individuals
of northern European descent and 72 Afro–Caribbean individu-
als from the Dutch Antilles. In addition to screening SNPs within
TGFBM2 (Benzinou et al., 2012) and TGFBM3 (Kawasaki et al.,
2014), we screened tag-SNPs (n = 443) that covered 72 “candi-
date genes” selected on the basis of their involvement in TGF-β
or BMP signaling and/or their responses to TGF-β. We used
a modification of the transmission disequilibrium test (TDT),
namely Gamete Competition (GC) (Lange et al., 2001, 2005) to
screen for genetic association with the presence vs. absence of
pulmonary AVM in HHT mutation carriers. GC was selected
over TDT because of the large, multigenerational structure of
families within this cohort. In addition to the previously pub-
lished genetic associations (Benzinou et al., 2012; Kawasaki et al.,
2014) 17 of the 443 SNPs tagging candidate genes showed nomi-
nal evidence of over-transmission to pulmonary AVM+ in Dutch
HHT patients (P < 0.05, GC test), and were genotyped in an
additional 108 northern European Dutch individuals (Extension
study). Genotyping of the first Dutch cohort was performed using
750-ng labeled genomic DNA hybridized to a custom Illumina
chip. Genotyping for the Dutch extension and French replica-
tion studies was performed using Sequenom MALDI-TOF mass
spectrometry. No significant difference in call rates between cases
and controls was seen. Samples successfully genotyped in <95%
of markers were excluded from analysis. Markers were excluded
if they deviated significantly from Hardy–Weinberg equilibrium
(P < 0.05, Hardy–Weinberg) or if they had a call rate <95% in
the entire cohort.
EXTRACTION OF RNA FROM AMUS SPRETUS ×MUS MUSCULUS F1
BACKCROSS
All animal experiments were approved a priori by the UCSF
IACUC. Backcross mice were generated by crossing inbred male
SPRET/Ei with inbred female FVB/N mice (Jackson Laboratory).
Female F1 hybrids were then mated to male FVB/N mice. Lungs
from eight-week-old mice were snap-frozen, and RNA was iso-
lated using TRIzol (Invitrogen) according to the manufacturer’s
instructions. Residual contaminating genomic DNAwas removed
by DNase treatment (Ambion).
qRT-PCR TAQMAN ANALYSIS
PCR was conducted in triplicate with 20μL reaction volumes
of 1X Taqman buffer (1X Applied Biosystems PCR buffer,
20% glycerol, 2.5% gelatin, 60nM Rox as a passive reference),
5.5mM MgCl2, 0.5mM each primer, 0.2μM each deoxynu-
cleotide triphosphate (dNTP), 200 nM probe, and 0.025 unit/μL
AmpliTaq Gold (Applied Biosystems) with 5 ng cDNA. A large
master mix of the above-mentioned components (minus the
primers, probe, and cDNA) was made for each experiment and
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aliquoted into individual tubes, one for each cDNA sample.
cDNA was then added to the aliquoted master mix. The mas-
ter mix with cDNA was aliquoted into a 384-well plate. The
primers and probes were mixed together and added to the mas-
ter mix and cDNA in the 384-well plate. PCR was conducted
on the ABI 7900HT (Applied Biosystems) using the following
cycle parameters: 1 cycle of 95◦ for 10min and 40 cycles of
95◦ for 15 s, 60◦ for 1min. SDS Analysis (version 2.3) supplied
with ABI 7900HT, was used to determine the Ct values of each
reaction.
Ct values were determined for three test and three refer-
ence reactions in each sample, averaged, and subtracted to
obtain the Ct [Ct = Ct (test locus) − Ct (control locus)].
PCR efficiencies were measured for all custom assays and were
=90%. Therefore, relative fold difference was calculated for each
primer/probe combination as 2−Ct × 100.
Primer probe combinations were either generated in house
(mouse Gus and rat Gapdh):
Gus
Forward: CTCATCTGGAATTTCGCCGA
Reverse: GGCGAGTGAAGATCCCCTTC
Probe: CGAACCAGTCACCGCTGAGAGTAATCG
GapDH
Forward: TGCACCACCAACTGCTTAG
Reverse: GGATGCAGGGATGATGTTC
Probe: CAGAAGACTGTGGATGGCCCCTC
or purchased as proprietary reagents from ABI-Life
Technologies Inc:
Eng, mCG18573: Assay ID: Mm00468256_m1
Acvrl1, mCG16831: Assay ID: Mm00437432_m1
Ptpn14, mCG19670: Assay ID: Mm00501215_m1
RESULTS
GENETIC VARIATION IN THE FUNCTIONAL ENG ALLELE ASSOCIATES
WITH PULMONARY AVMs IN HHT1
As previously reported, a candidate screen for genetic associa-
tion to pulmonary AVMs in HHT patients showed that PTPN14
within the TGFBM2 locus showed the strongest genetic associ-
ation to pulmonary AVM incidence in both HHT1 and HHT2
mutation carriers (Benzinou et al., 2012). However, as pre-
sented here, additional SNPs within several candidate genes
showed suggestive association within the Dutch HHT population
(see Supplementary Table S1). Interestingly, in the Dutch HHT
cohort, primarily within HHT1, we found evidence of suggestive
genetic association between the prevalence of pulmonary AVMs
in three out of seven tagSNPs spanning the HHT1 causative gene,
ENG (P = 5.4 × 10−3 for the intronic SNP rs10987746 in HHT1;
GC test, Supplementary Table S2), and a similar observation
was made within the French HHT1 population (rs1887266,P =
0.005; rs10987746;P = 0.087; Supplementary Table S3). Our ini-
tial analysis did not differentiate between the two alleles of
the mutated causative gene. We therefore considered that this
observation might be artifactual, driven by linkage disequilib-
rium between the test SNP and the causative ENG mutation.
Since most causative HHT mutations are loss of function, we
surmised that genetic variants within the mutated gene would
be functionally inconsequential whereas genetic variation within
the wild type allele, inherited from the unaffected parent, may
influence the clinical features of HHT. In order to interrogate
this further, we limited our analysis to those Dutch HHT fam-
ilies for whom the genetic phase of the causative mutation
could be determined. Pedigree analysis permitted us to eluci-
date the genetic phase of ENG rs10987746 with respect to the
causative vs. wild type ENG alleles in 266 HHT1 cases from 80
families. We tested for genetic association between rs10987746
within the wild type ENG allele and the prevalence of pul-
monary AVMs in Dutch HHT1, and confirmed the notion that
genetic variation within the functional ENG allele inherited from
the non-affected parent associates with presence of pulmonary
AVM in HHT1 (rs10987746-C relative risk = 1.3 (1.0018–1.7424)
(Table 1).
POSSIBLE GENETIC ASSOCIATION BETWEEN ACVRL1 AND
PULMONARY AVMs IN HHT2
A similar effect to that seen with ENGmay occur for the wild type
ACVRL1 allele in HHT2. Indeed, four out of six tagSNPs that span
the two adjacent loci ACVRL1 and ACVR1B showed genetic asso-
ciation with pulmonary AVMs in Dutch HHT2 patients (P <
0.05;GC test, Supplementary Table S2). However, there were
insufficient HHT2 specimens within the Dutch HHT population
to undertake genetic phase analysis for ACVRL1, and extensive
pedigree information was not available for the French cohort, pre-
empting an analysis of the effect of variation in the functional
ACVRL1 allele on pulmonary AVM incidence.
SUGGESTIVE GENETIC ASSOCIATION BETWEEN EMILIN2 VARIANTS
AND PULMONARY AVMs IN HHT PATIENTS
SNPs within several other candidate genes showed sugges-
tive association (p < 0.05) within the Dutch HHT pop-
ulation (see Supplementary Table S1). Of three EMILIN2
SNPs tested, one showed significant (P = 0.023) and one
showed a trend toward (P = 0.09) association with the pres-
ence of pulmonary AVMs in the French HHT validation
cohort (Supplementary Table S3). SNPs in other candidate
genes with association in the Dutch screen did not vali-
date in the French HHT cohort (not shown). The EMILIN2
association with pulmonary AVMs was weak, but was found
in HHT1 only (not HHT2) in both the French and Dutch
cohorts. It could represent a false positive due to issues with
multiple testing, thus functional validation remains to be
undertaken.
Table 1 | Genetic variation in the wild type ENG allele, inherited from
the unaffected parent, associates with presence of pulmonary AVMs
in HHT1 patients.
rs10987746 genotype of HHT1 patients HHT1 patients
wild type ENG allele with pulmonary AVM no pulmonary AVM
T 63 (44.4%) 79 (55.6%)
C 70 (56.5%) 54 (43.5%)
Relative risk of pulmonary AVMs = 1.3 (95% confidence interval = 1.002–1.742)
P = 0.018.
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THE PULMONARY AVM-PROTECTIVE ENG ALLELE ASSOCIATES WITH
HIGHER ENG EXPRESSION IN HUMAN LB CELL LINES AND TRENDS
WITH HIGHER PTPN14 EXPRESSION
rs1887266 is a 5′ flanking SNP and rs10987746 is located within
intron 12 near the 3′ end of the gene. These might associate
with quantitative differences in ENG transcript levels and/or with
differential ENG splicing resulting in qualitative differences in
endoglin protein. We undertook eQTL analysis on publically
available genome wide SNP and microarray expression data from
61CEPH lymphoblastoid (LB) cell lines for which rs10987746 had
been genotyped, to investigate whether this SNP might show cor-
relation to expression of ENG message levels. ENG mRNA was
expressed at low levels in these cell lines (Figure 1A) and the fre-
quency of rs10987746 –C homozygosity was exceedingly low (n =
7), precluding a statistically robust comparative analysis of ENG
transcript levels in rs10987746–CC genotype vs. rs10987746-TC
or rs10987746-TT genotypes. However, using a dominant model
of action for the pulmonary AVM-at-risk allele, rs10987746-C, we
found significant association with lower ENG expression levels
(P = 4 × 10−3, ANOVA) (Figure 1A).
Since genetic variation within PTPN14 is also a genetic risk
factor for pulmonary AVMs inHHT1 andHHT2 (Benzinou et al.,
2012), we examined association between ENG-rs10987746-C and
expression of PTPN14 transcript levels in the human LB dataset.
PTPN14 expression in the CEPH LB cell panel was lower than
that of ENG and there was a trend toward association between
rs10987746-C and lower PTPN14 gene expression, although this
did not reach significance (P = 0.08,ANOVA; Figure 1B).
IN ANGIOGENICALLY ACTIVE HUMAN LUNG TUMOR TISSUE, BUT NOT
IN NORMAL LUNG, THE PULMONARY AVM AT-RISK ENG SNP
ASSOCIATES WITH HIGHER PTPN14 EXPRESSION
Since the target organ of interest in this study is lung, we
undertook eQTL analysis in a panel of human lung tissues. We
genotyped rs10987746 in genomic DNA and interrogated gene
expression levels of ENG and PTPN14 in 111 paired samples
of human primary pulmonary adenocarcinomas and matched
uninvolved lung tissue from the same individual collected from
lung cancer patients who had undergone debulking surgery for
their cancer (Kim et al., 2013). We found that, in the uninvolved
“normal” human lung tissue, which is angiogenically quiescent,
PTPN14 gene expression levels were high but showed little varia-
tion across the panel (∼= 2 fold) precluding robust eQTL analysis
(Supplementary Figure S1). On the other hand, in the primary
lung adenocarcinoma samples, although PTPN14 expression lev-
els were lower than in the adjacent unaffected lung, they showed
more variation between individuals across the panel (∼= 4 fold).
Intriguingly, eQTL analysis showed association between the pul-
monary AVM-associated ENG SNP, rs10987746-C, and higher
expression of PTPN14 in this angiogenically-active adenocarci-
noma tissue (P = 4 × 10−3, Figure 2), whereas ENG transcript
levels were not correlated with rs10987746 in either normal or
neoplastic lung tissue.
EXPRESSION OF ENG, ACVRL1, AND PTPN14 ARE STRONGLY
CORRELATED IN A GENETICALLY DIVERSE PANEL OF MOUSE LUNGS
As PTPN14 gene expression levels were relatively homogeneous
across the panel of normal angiogenically quiescent human lung
tissues, we turned to a genetically heterogeneous mouse model to
interrogate possible correlations between gene expression of the
two HHT causative genes, Eng and Acvrl1, with the pulmonary
AVM modifier, Ptpn14. An F1 inter-specific mouse backcross
between the two inbred mouse species,Mus spretus andMus mus-
culus FVB/Ola provides even greater genetic heterogeneity than
seen within the human population, such that individual genes
show a wider dynamic range of expression levels between individ-
ual mice, thus permitting more powerful expression correlation
analysis (Quigley et al., 2009; Kim et al., 2013; Sjolund et al.,
FIGURE 1 | ENG SNP rs10987746 correlates with ENG RNA levels in
human LB cell lines. (A) ENG and (B) PTPN14 expression was
assessed according to rs10987746 genotype in data derived from LB cell
lines from Utah residents of Northern and Western European Ancestry
from the CEPH collection (CEU) (Cheung et al., 2005). The
rs10987746-C/C genotype was unusually underrepresented in this panel
(n = 7), and showed no statistically significant difference in expression
from the rs10987746 -T/C genotype, hence these two genotypes were
pooled. The mean gene expression and the 95% confidence interval of
this mean are plotted for each genotype.
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FIGURE 2 | ENG SNP rs10987746 correlates with PTPN14 but not ENG
expression levels in human primary pulmonary adenocarcinoma tissue,
but not in normal lung. (A) ENG and (B) PTPN14 expression was plotted vs.
rs10987746 genotype in RNAs extracted from a panel of 111 primary human
lung adenocarcinoma samples (A,B) and matched uninvolved lung tissue from
the same patients (insignificant see Supplementary Figure S1). The mean
gene expression and the 95% confidence interval of this mean are shown for
each genotype. Gene expression data was ascertained using Illumina human-6
v2.0 expression beadchip technology (Kim et al., 2013) (GEO GSE32665) and
P-values (ANOVA) were calculated using Tukey’s HSD in R.
2014). We quantified relative expression levels of Eng, Acvrl1, and
Ptpn14 transcripts across this inter-specific normal mouse lung
panel and found that the three test genes showed highly corre-
lated expression levels with each other (Spearman’s rho values
from 0.75 to 0.9, P = 1 × 10−12; Figure 3). This suggests that
Eng, Acvrl1, and Ptpn14may all be expressed in the same lung cell
type (Quigley et al., 2009; Kim et al., 2013), presumably endothe-
lial, and that they are possibly co-regulated within that cell type
(Sjolund et al., 2014). However, the data cannot exclude the possi-
bility that tight expression correlation is due to crosstalk between
two intimately interacting cell types.
DISCUSSION
The identification of modifier genes can be informative for elu-
cidating possible molecular mechanisms regulating variable pen-
etrance and expressivity of clinical symptoms of disease. In the
current study we show that genetic variation in the wild type
ENG allele, inherited from the unaffected parent, modifies HHT
clinical outcome in terms of presence of pulmonary AVMs in
HHT1. We found that the pulmonary AVM-at-risk allele, ENG-
rs10987746-C, associates with a small but significant reduction
in ENG transcript levels in a panel of human LB cell line data,
and we demonstrate significant expression interaction between
ENG, ACVRL1, and the pulmonary AVM modifier, PTPN14, by
eQTL analysis and by expression correlation analysis of mouse
and human lung tissue in vivo. We also report suggestive associa-
tion between SNPs in EMILIN2, which encodes the extracellular
matrix protein, elastin microfibril interfacer 2, in two indepen-
dent cohorts of HHT1 patients from Netherlands and France.
There have been previous reports of genetic association
between SNPs in ACVRL1 and ENG with sporadic brain
AVMs in North American and Northern European Caucasians.
Pawlikowska et al. (2005) demonstrated association of sporadic
brain AVMs with ACVRL1-rs2071219, and marginal association
with ENG-rs16930129 (P = 0.002) and ENG-rs10987759 (P =
0.09) in 177 sporadic brain AVMpatients vs. 129 healthy controls.
Simon et al. (2006) replicated the association between ACVRL1-
rs2071219 with brain AVMs or dural arteriovenous fistulas in a
Northern European cohort, but were unable to show such asso-
ciation with ENG SNPs. Conversely, ACVRL1-rs2071219 associ-
ation with sporadic brain AVMs was not reproduced in a more
recent study of 143 Dutch Caucasian patients vs. 360 ethnically
matched healthy volunteers (Boshuisen et al., 2013).WithinHHT,
Boshuisen et al. (2013) screened for genetic association between
ENG SNPs and presence of brain AVMs within the Dutch HHT1
population by matched pair analysis of 24 HHT1 patients with
brain AVMs vs. 24 HHT1 relatives with no brain AVM, but they
were unable to show genetic association, possibly due to small
sample sizes of the brain AVM-positive HHT1 population. In the
current study, we genotyped larger numbers of HHT1 patients
and focused on pulmonary AVMs which is more common than
brain AVM. We were able to screen for genetic association to
the wild type ENG allele in 266 affected HHT1 individuals from
35 families, for whom we could deduce the phase of the wild
type ENG SNP. We found weak but significant genetic association
between the inheritance of a wild type ENG rs10987746-C allele
and increased risk of pulmonary AVMs in HHT1.
Here we complemented our previous HHT studies impli-
cating PTPN14 as a genetic modifier of pulmonary AVMs by
demonstrating strong expression correlation between Eng, Acvrl1,
and Ptpn14 transcript levels in normal wild type mouse lung
tissues. Our previous studies utilizing correlation gene expres-
sion network analysis of interspecific mouse backcrosses have
demonstrated the power of this technique to define not only cell-
type-specific co-expression, but to identify genes whose protein
products show direct physical or functional interactions within
tissues (Quigley et al., 2009; Sjolund et al., 2014). The strong cor-
relation between expression of these three genes, together with
expression of other endothelial-specific genes (data not shown),
suggests that in normal mouse lung Ptpn14, Eng, and Acvrl1 are
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FIGURE 3 | Eng, Acvrl1, and Ptpn14 gene expression are highly
correlated in normal mouse lung tissues. RNA extracted from a panel of
69 wild type healthy mouse lungs from an F1 inter-specific mouse backcross
between Mus spretus and Mus musculus FVB/Ola, was subjected to
TAQMAN qRT-PCR analysis with five probes, Eng, Acvrl1, Ptpn14, Gus, and
Gapdh. (A–C) show pair-wise correlations for expression of the two probes
indicated in each of the 69 samples. Eng, Acvrl1, and Ptpn14, expression are
normalized against Gapdh. The data showed a similar strong correlation when
normalized against Gus (not shown). Non-parametric Spearman Rank
correlations shown were calculated in R.
predominantly co-expressed within the same cell type, namely
endothelial. However, there are currently no PTPN14-specific
antibodies that perform well for immunohistochemical analysis
to test this possibility.
We found that the pulmonary AVM-at-risk allele rs10987746-
C associated with a slight but significantly lower level of ENG
RNA in a human LB cell line panel, providing supporting evi-
dence that genetic variation within this gene may influence its
own expression. Conversely, in a panel of RNAs extracted from
human primary lung adenocarcinomas and from adjacent normal
lung tissue, there was no correlation between ENG rs10987746
and ENG expression level. This may, in part, be due to the techni-
cal limitations of working with primary human tissues compared
to cell lines, and due to differences in the technological plat-
forms used for gene expression analysis in the two experiments.
However, in the human lung tumor tissues rs10987746 did show
correlation with expression levels of PTPN14, despite lack of asso-
ciation with ENG transcript levels. A possible explanation is that
this SNP is associated with differential post-transcriptional or
translational control of endoglin levels that subsequently affect
PTPN14 expression. rs10987746 lies within an antisense tran-
script showing 300 nt complementarity to the ENG mRNA that
might contribute to regulation of ENG in either cis or trans.
Additionally, rs10987746 is proximal to the penultimate ENG
exon which is subject to differential splicing to generate two
structurally distinct and functionally antagonistic endoglin pro-
tein isoforms differing within their intracellular domains (Bellon
et al., 1993; Lopez-Novoa and Bernabeu, 2010). Whether or not
rs10987746 associates with differential ENG splicing, remains to
be tested. Overall, however, we conclude that correlations between
ENG, ALK1, and PTPN14 expression in both mouse and human
lung tissues, support our previous in vitro studies of recipro-
cal regulation between ACVRL1 and PTPN14 in primary human
endothelial cells, and genetic association between PTPN14 and
risk of pulmonary AVMs in HHT (Benzinou et al., 2012).
Since publishing our findings on PTPN14 involvement in
HHT (Benzinou et al., 2012), several papers have demonstrated
that, in epithelial cells, PTPN14 is a negative regulator of the
transcriptional cofactors, Yap, and Taz (Huang et al., 2012; Liu
et al., 2012; Wang et al., 2012; Wilson et al., 2014). These proteins
are targets of the Hippo kinase pathway, originally identified as a
master regulator of cell and organ size, mediator of contact inhibi-
tion and regulator of stem cell maintenance (Barry and Camargo,
2013; Hiemer and Varelas, 2013). More recently, Hippo signaling
has been found to be a major regulator of mechanotransduc-
tion in both epithelial and endothelial cells (Dupont et al., 2011;
Sansores-Garcia et al., 2011; Wada et al., 2011; Zhao et al., 2012;
Aragona et al., 2013). Intriguingly, EMILIN2, which showed sug-
gestive association with pulmonary AVMs and which is known to
regulate angiogenesis, has also been reported to regulate Taz activ-
ity (Marastoni et al., 2014), suggesting some commonality in the
downstream pathways of two pulmonary AVMmodifier genes.
Blood vessels, in particular, are subject to constant shear stress
and remodeling, suggesting that disruption of endothelial cell sig-
naling pathways that regulate mechanotransduction within the
vascular bed may contribute to defects in vascular remodeling
and AVM susceptibility (Roman and Pekkan, 2012). The Roman
group previously demonstrated an important link between the
fish orthologue of ACVRL1, alk1, and regulation of mechan-
otransduction when using the zebrafish as a model system. They
demonstrated not only that alk1 expression in arterial endothe-
lial cells requires blood flow, but that under normal shear stress
conditions a subset of flow-responsive genes are dysregulated in
alk1 mutant arterial endothelial cells (Corti et al., 2011). They
proposed a model whereby blood flow, under normal conditions,
not only activates alk1 expression, but delivers cardiac-derived
Bmp10 to activate an Alk1-responsive (flow-responsive) gene
expression program that limits nascent arterial caliber (Laux et al.,
2013). The interaction between PTPN14, endoglin, and ALK1
in mouse and human tissues provides another molecular link
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between the HHT causative genes and the mechanotransduction
pathway. It will be important to elucidate the detailed molecu-
lar mechanisms regulating these interactions in endothelial cells,
particularly within the lung, since this might lead tomore rational
choices for HHT therapy.
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